Interactions Between Breast Cancer Susceptibility Loci and Menopausal Hormone Therapy in Relationship to Breast Cancer in the Breast and Prostate Cancer Cohort Consortium

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2016 Jan 24

PMID 26802016

Authors

Mia M Gaudet

Myrto Barrdahl

Sara Lindstrom

Ruth C Travis

Paul L Auer

Julie E Buring

Stephen J Chanock

A Heather Eliassen

Susan M Gapstur

Graham G Giles

Marc Gunter

Christopher Haiman

David J Hunter

Amit D Joshi

Rudolf Kaaks

Kay-Tee Khaw

I-Min Lee

Loic Le Marchand

Roger L Milne

Petra H M Peeters

Malin Sund

Rulla Tamimi

Antonia Trichopoulou

Elisabete Weiderpass

Xiaohong R Yang

Ross L Prentice

Heather Spencer Feigelson

Federico Canzian

Peter Kraft

Affiliations

Soon will be listed here.

Abstract

Current use of menopausal hormone therapy (MHT) has important implications for postmenopausal breast cancer risk, and observed associations might be modified by known breast cancer susceptibility loci. To provide the most comprehensive assessment of interactions of prospectively collected data on MHT and 17 confirmed susceptibility loci with invasive breast cancer risk, a nested case-control design among eight cohorts within the NCI Breast and Prostate Cancer Cohort Consortium was used. Based on data from 13,304 cases and 15,622 controls, multivariable-adjusted logistic regression analyses were used to estimate odds ratios (OR) and 95 % confidence intervals (CI). Effect modification of current and past use was evaluated on the multiplicative scale. P values <1.5 × 10(-3) were considered statistically significant. The strongest evidence of effect modification was observed for current MHT by 9q31-rs865686. Compared to never users of MHT with the rs865686 GG genotype, the association between current MHT use and breast cancer risk for the TT genotype (OR 1.79, 95 % CI 1.43-2.24; P interaction = 1.2 × 10(-4)) was less than expected on the multiplicative scale. There are no biological implications of the sub-multiplicative interaction between MHT and rs865686. Menopausal hormone therapy is unlikely to have a strong interaction with the common genetic variants associated with invasive breast cancer.

References

Tworoger S, Sluss P, Hankinson S . Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 2006; 66(4):2476-82. DOI: 10.1158/0008-5472.CAN-05-3369. View

Smith-Warner S, Spiegelman D, Yaun S, Adami H, Beeson W, van den Brandt P . Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA. 2001; 285(6):769-76. DOI: 10.1001/jama.285.6.769. View

Hunter D, Riboli E, Haiman C, Albanes D, Altshuler D, Chanock S . A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005; 5(12):977-85. DOI: 10.1038/nrc1754. View

Sprague B, Trentham-Dietz A, Cronin K . A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012; 120(3):595-603. PMC: 3607288. DOI: 10.1097/AOG.0b013e318265df42. View

Chlebowski R, Anderson G, Gass M, Lane D, Aragaki A, Kuller L . Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010; 304(15):1684-92. PMC: 5142300. DOI: 10.1001/jama.2010.1500. View

. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1999; 350(9084):1047-59. View

Anderson G, Limacher M, Assaf A, Bassford T, Beresford S, Black H . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291(14):1701-12. DOI: 10.1001/jama.291.14.1701. View

Rexrode K, Lee I, Cook N, Hennekens C, Buring J . Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000; 9(1):19-27. DOI: 10.1089/152460900318911. View

Figueroa J, Garcia-Closas M, Humphreys M, Platte R, Hopper J, Southey M . Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011; 20(23):4693-706. PMC: 3209823. DOI: 10.1093/hmg/ddr368. View

10.

Manson J, Chlebowski R, Stefanick M, Aragaki A, Rossouw J, Prentice R . Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13):1353-68. PMC: 3963523. DOI: 10.1001/jama.2013.278040. View

11.

Ellingjord-Dale M, Grotmol T, Lee E, Van Den Berg D, Hofvind S, Couto E . Breast cancer susceptibility variants and mammographic density phenotypes in norwegian postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2014; 23(9):1752-63. DOI: 10.1158/1055-9965.EPI-13-1212. View

12.

Warren H, Dudbridge F, Fletcher O, Orr N, Johnson N, Hopper J . 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2012; 21(10):1783-91. PMC: 3772723. DOI: 10.1158/1055-9965.EPI-12-0526. View

13.

. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998; 19(1):61-109. DOI: 10.1016/s0197-2456(97)00078-0. View

14.

Milne R, Gaudet M, Spurdle A, Fasching P, Couch F, Benitez J . Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Res. 2011; 12(6):R110. PMC: 3046455. DOI: 10.1186/bcr2797. View

15.

Campa D, Kaaks R, Le Marchand L, Haiman C, Travis R, Berg C . Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst. 2011; 103(16):1252-63. PMC: 3156803. DOI: 10.1093/jnci/djr265. View

16.

Bojesen S, Pooley K, Johnatty S, Beesley J, Michailidou K, Tyrer J . Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013; 45(4):371-84, 384e1-2. PMC: 3670748. DOI: 10.1038/ng.2566. View

17.

Beral V . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362(9382):419-27. DOI: 10.1016/s0140-6736(03)14065-2. View

18.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

19.

Schoeps A, Rudolph A, Seibold P, Dunning A, Milne R, Bojesen S . Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. Genet Epidemiol. 2013; 38(1):84-93. PMC: 3995140. DOI: 10.1002/gepi.21771. View

20.

Hayes R, Reding D, Kopp W, Subar A, Bhat N, Rothman N . Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2001; 21(6 Suppl):349S-355S. DOI: 10.1016/s0197-2456(00)00101-x. View